Montis Biosciences develops anti-C1q antibodies that target complement-independent functions of C1q to treat neuroinflammatory and autoimmune disorders, as well as CD93 inhibitors for lung squamous cell carcinoma. The company addresses severe chronic inflammation-driven diseases by enhancing the immune gatekeeping function of the perivascular microenvironment.
Funding
$11.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many neurodegenerative diseases, autoimmune disorders, and cancers are driven by chronic inflammation, which existing therapies often fail to adequately address. Current C1q-targeting approaches for neuroinflammatory and autoimmune disorders primarily focus on blocking the classical complement pathway, potentially overlooking other key functions of C1q. Lung squamous cell carcinoma (LUSC) remains an underserved oncology indication with limited treatment options targeting the perivascular microenvironment.
Solution
Montis Biosciences is developing novel therapeutics to treat severe, chronic inflammation-driven diseases by enhancing the immune gatekeeping function of the perivascular microenvironment. Their lead program, MB01, utilizes anti-C1q antibodies capable of targeting C1q's complement-independent functions, with or without inhibiting the classical complement cascade, offering a potential paradigm shift in treating certain neurodegenerative diseases and autoimmune neuropathies. Montis' second program, MB02, focuses on inhibiting CD93, a novel perivascular target, in lung squamous cell carcinoma (LUSC), holding best-in-class potential in this inflammation-driven oncology indication. These antibodies hold the potential to revolutionize treatments for certain neurodegenerative diseases and autoimmune neuropathies.
Target Audience
The primary target audience includes patients suffering from neurodegenerative diseases, autoimmune disorders, and lung squamous cell carcinoma, as well as pharmaceutical companies interested in partnering for the development of novel oncology therapeutics.
Features
- MB01: Novel anti-C1q antibodies targeting complement-independent functions.
- MB01: Ability to modulate C1q activity with or without inhibiting the classical complement cascade.
- MB01: Potential to initiate two Phase 1 clinical trials in neurodegenerative and autoimmune indications in 1H 2026.
- MB02: Inhibition of CD93, a novel perivascular target in LUSC.
- MB02: A potent drug candidate with best-in-class potential.
- Patient-centric discovery platform.